Abstract
Use of umbilical cord blood (CB) for stem cell transplantation has a number of advantages, but a major disadvantage is the relatively low cell number available. Ex vivo cell expansion has been proposed to overcome this limitation, and this study therefore evaluated the use of perfusion culture systems for CB cell expansion. CB was cryopreserved using standard methods and the thawed unpurified cells were used to initiate small-scale cultures supplemented with PIXY321, flt-3 ligand, and erythropoietin in serum-containing medium. Twelve days of culture resulted in the optimal output from most CB samples. Frequent medium exchange led to significant increases in cell (93%), CFU-GM (82%) and LTC-IC (350%) output as compared with unfed cultures. As the inoculum density was increased from 7.5 × 104 per cm2 to 6.0 × 105 per cm2, the output of cells, CFU-GM, and LTC-IC increased. Cell and CFU-GM output reached a plateau at 6.0 × 105 per cm2, whereas LTC-IC output continued to increase up to 1.2 × 106 per cm2. Because the increase in culture output did not increase linearly with increasing inoculum density, expansion ratios were greatest at 1.5 × 105 per cm2 for cells (6.4-fold) and CFU-GM (192-fold). Despite the lack of adherent stroma, CB cultures expressed mRNA for many growth factors (G-CSF, GM-CSF, IL-1, IL-6, LIF, KL, FL, Tpo, TGF-β, TNF-α, and MIP-1α) that were also found in bone marrow (BM) cultures, with the exception of IL-11 (found only in BM) and IL-3 (found in neither). Culture output was remarkably consistent from 10 CB samples (coefficient of variation 0.3) indicating that the procedure is robust and reproducible. Two commercial serum-free media were evaluated and found to support only approximately 25% of the culture output as compared with serum-containing medium. Implementation of optimal conditions in the clinical scale, automated cell production system (CPS) showed that the process scaled-up well, generating 1.7 × 107 CFU-GM (298-fold expansion) from 1.2 × 108 thawed viable nucleated CB cells (n = 3). The ability to generate >107 CFU-GM from <15 ml of cb within this closed, automated system without the need for extensive cell manipulations will enable clinical studies to test the safety and efficacy of expanded cb cells in the transplant setting.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koller, M., Manchel, I., Maher, R. et al. Clinical-scale human umbilical cord blood cell expansion in a novel automated perfusion culture system. Bone Marrow Transplant 21, 653–663 (1998). https://doi.org/10.1038/sj.bmt.1701157
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701157
Keywords
This article is cited by
-
Ex vivo expansion of hematopoietic stem cells
Science China Life Sciences (2015)
-
Ex vivo expansion of umbilical cord blood: where are we?
International Journal of Hematology (2012)
-
Formation of an adherent hematopoietic expansion culture using fucoidan
Annals of Hematology (2011)
-
Optimization of ex vivo hematopoietic stem cell expansion in intermittent dynamic cultures
Biotechnology Letters (2010)
-
Ex vivo expansion of cord blood
Bone Marrow Transplantation (2009)